trending Market Intelligence /marketintelligence/en/news-insights/trending/QfHyDTT8IMkokPK8BI1_2w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UK's NICE rejects J&J's bowel disease drug Stelara in draft guidance

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


UK's NICE rejects J&J's bowel disease drug Stelara in draft guidance

The U.K. National Institute for Health and Care Excellence did not recommend the use of Johnson & Johnson's Stelara for active ulcerative colitis, citing uncertainties on the drug's cost-effectiveness.

Stelara, or ustekinumab, is approved in the U.S. and EU to treat adults with moderately to severely active ulcerative colitis, as well as plaque psoriasis, psoriatic arthritis and Crohn's disease. The drug is being developed by New Brunswick, N.J.-based pharmaceutical giant's Janssen unit.

Ulcerative colitis is a chronic condition characterized by inflammation and ulcers in the bowel and rectum, which could cause bleeding and produce pus.

In its draft guidance, NICE said Stelara cannot be recommended for use in England's National Health Service as a treatment option for adults with moderate to severe active ulcerative colitis when conventional therapy or a biological agent cannot be tolerated. The drug's indication also covers patients whose disease showed inadequate or lost response to treatment.

The initial guidance was based on cost-effectiveness estimates which differ from slightly below to above the range of what the pricing watchdog considers as cost-effective, NICE noted.

Stelara has a list price of £2,147 per 130-milligram vial of concentrate for solution for infusion and £2,147 for each 90-milligram vial of solution for injection. Meanwhile, annual treatment costs are £14,482 in the induction year and £9,304 each year for maintenance treatment for the second year onward.

NICE said its draft guidance is still subject to consultation and will be open for comments and feedback until Feb. 11.